Cargando…

Self-Propelling Targeted Magneto-Nanobots for Deep Tumor Penetration and pH-Responsive Intracellular Drug Delivery

Self-propelling magnetic nanorobots capable of intrinsic-navigation in biological fluids with enhanced pharmacokinetics and deeper tissue penetration implicates promising strategy in targeted cancer therapy. Here, multi-component magnetic nanobot designed by chemically conjugating magnetic Fe(3)O(4)...

Descripción completa

Detalles Bibliográficos
Autores principales: Andhari, Saloni S., Wavhale, Ravindra D., Dhobale, Kshama D., Tawade, Bhausaheb V., Chate, Govind P., Patil, Yuvraj N., Khandare, Jayant J., Banerjee, Shashwat S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070039/
https://www.ncbi.nlm.nih.gov/pubmed/32170128
http://dx.doi.org/10.1038/s41598-020-61586-y
Descripción
Sumario:Self-propelling magnetic nanorobots capable of intrinsic-navigation in biological fluids with enhanced pharmacokinetics and deeper tissue penetration implicates promising strategy in targeted cancer therapy. Here, multi-component magnetic nanobot designed by chemically conjugating magnetic Fe(3)O(4) nanoparticles (NPs), anti-epithelial cell adhesion molecule antibody (anti-EpCAM mAb) to multi-walled carbon nanotubes (CNT) loaded with an anticancer drug, doxorubicin hydrochloride (DOX) is reported. Autonomous propulsion of the nanobots and their external magnetic guidance is enabled by enriching Fe(3)O(4) NPs with dual catalytic-magnetic functionality. The nanobots propel at high velocities even in complex biological fluids. In addition, the nanobots preferably release DOX in the intracellular lysosomal compartment of human colorectal carcinoma (HCT116) cells by the opening of Fe(3)O(4) NP gate. Further, nanobot reduce ex vivo HCT116 tumor spheroids more efficiently than free DOX. The multicomponent nanobot’s design represents a more pronounced method in targeting tumors with self-assisted anticancer drug delivery for ‘far-reaching’ sites in treating cancers.